Two Sigma Advisers
RNAC icon

Two Sigma Advisers’s Cartesian Therapeutics RNAC Stock Holding History

Two Sigma Advisers’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,808
Closed -$179K – 1710
2025
Q4 		$179K Buy
+24,808
New +$201K ﹤0.01% 2141
2023
Q3 		– Sell
-3,703
Closed -$124K – 2546
2023
Q2 		$124K Sell
3,703
-10,984
-75% -$393K ﹤0.01% 2185
2023
Q1 		$612K Sell
14,687
-5,406
-27% -$254K ﹤0.01% 1861
2022
Q4 		$681K Sell
20,093
-9,470
-32% -$403K ﹤0.01% 1751
2022
Q3 		$1.46M Buy
29,563
+5,156
+21% +$283K ﹤0.01% 1338
2022
Q2 		$959K Sell
24,407
-22,393
-48% -$664K ﹤0.01% 1618
2022
Q1 		$1.73M Sell
46,800
-4,440
-9% -$278K ﹤0.01% 1347
2021
Q4 		$5.01M Buy
51,240
+770
+2% +$82.8K 0.01% 763
2021
Q3 		$6.3M Sell
50,470
-4,597
-8% -$555K 0.02% 687
2021
Q2 		$6.91M Sell
55,067
-4,596
-8% -$547K 0.02% 713
2021
Q1 		$8.1M Buy
59,663
+4,660
+8% +$579K 0.02% 654
2020
Q4 		$5M Buy
55,003
+24,246
+79% +$2.1M 0.01% 816
2020
Q3 		$2.29M Buy
30,757
+20,500
+200% +$1.57M 0.01% 1090
2020
Q2 		$874K Buy
10,257
+6,694
+188% +$607K ﹤0.01% 1640
2020
Q1 		$258K Buy
3,563
+1,080
+43% +$104K ﹤0.01% 2076
2019
Q4 		$177K Sell
2,483
-57
-2% -$2.75K ﹤0.01% 2207
2019
Q3 		$133K Sell
2,540
-310
-11% -$16.5K ﹤0.01% 2091
2019
Q2 		$153K Sell
2,850
-860
-23% -$58.6K ﹤0.01% 2169
2019
Q1 		$264K Buy
3,710
+1,880
+103% +$119K ﹤0.01% 2031
2018
Q4 		$146K Buy
1,830
+283
+18% +$64.6K ﹤0.01% 2182
2018
Q3 		$722K Buy
1,547
+464
+43% +$186K ﹤0.01% 1641
2018
Q2 		$431K Buy
1,083
+330
+44% +$117K ﹤0.01% 1974
2018
Q1 		$230K Buy
753
+266
+55% +$75.8K ﹤0.01% 2103
2017
Q4 		$143K Buy
+487
New +$213K ﹤0.01% 2122

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's RNAC Position: Q1 2026 in Review

Two Sigma Advisers sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 24,808 shares — an estimated $179K sold.

Two Sigma Advisers first reported a position in RNAC in Q4 2017 and held it in 24 quarters. The position peaked at $8.1M in Q1 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Two Sigma Advisers reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 24,808 Cartesian Therapeutics shares in Q1 2026, an estimated $179K.
  • Two Sigma Advisers first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 24 quarters.
  • Two Sigma Advisers's Cartesian Therapeutics position peaked at $8.1M in Q1 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.